Viewing Study NCT00726869


Ignite Creation Date: 2025-12-24 @ 11:04 PM
Ignite Modification Date: 2025-12-31 @ 3:07 PM
Study NCT ID: NCT00726869
Status: TERMINATED
Last Update Posted: 2012-08-23
First Post: 2008-07-29
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies.
Sponsor: Abbott
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module